drugset
drugset / Trial / NCT06044493

MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

NCT06044493 ↗

Phase 4 Completed 158 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients

Timeline

Start
2023-11-14
Primary completion
2025-10-29
Completion
2025-10-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mycophenolate Mofetil Small molecule 1 g —
Subject Myreptic-N Unknown 720 mg —

Indications

No indication recorded.